Journal of V. N. Karazin Kharkiv National University: Series Medicine · Published 2026-04-27 · DOI 10.26565/2313-6693-2026-59-01
Background. The study of sclerostin is of particular clinical interest in patients with chronic kidney disease stage V and diabetes mellitus, because today it is an insufficiently studied biomarker of bone metabolism disorders, potentially associated with vascular calcification in hyperazotemia conditions. Purpose – to determine the clinical significance of serum sclerostin in patients with chronic kidney disease VD stage and diabetes mellitus by analyzing its relationships with key clinical and laboratory parameters. Materials and methods. A single-center cross-sectional cohort study was conducted in which 134 patients with chronic kidney disease stage VD were examined. All patients were determined by the level of vitamin D (25(OH)D), C-reactive protein, lipid profile, urea, creatinine, total protein and albumin, ferritin, intact parathyroid hormone, calcium, phosphorus, alkaline phosphataseactivity. The level of circulating sclerostin was determined using an automated enzyme-linked immunosorbent assay – ELISA SOST for humans (ab221836). Result. In patients with chronic kidney disease stage VD and diabetes mellitus, lower levels of intact parathyroid hormone were found, which were associated with higher levels of serum sclerostin; a higher frequency of heart valvular apparatus calcification, which was accompanied by an increase in the frequency of vertebral and non-vertebral fractures against the background of vitamin D(25(OH)D) severe deficiency. Lipid metabolism disorders in the form of hypercholesterolemia and hypertriglyceridemia, combined with a higher level of serum ferritin were detected in the group with diabetes mellitus. A positive correlation was found between body mass index and sclerostin (r = 0.448; p = 0.008), urea level and sclerostin (r = 0.364; p = 0.034). There was a negative correlation between intact parathyroid hormone level and sclerostin (r = -0.371; p = 0.031); alkaline phosphatase and sclerostin (r = -0.401; p = 0.025); total plasma protein level and sclerostin (r = -0.368; p = 0.032). Conclusion. Chronic kidney disease stage V on dialysis and diabetes mellitus have profound disorders of mineral and lipid metabolism. The results indicate significance of sclerostin as a modern biomarker in the diagnosis of mineral and bone disorders in patients with chronic kidney disease stage V on dialysis.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →